REMS Assessment Paradigm To Be RE-AIMed By FDA; “Pressure-Testing” Needed
Executive Summary
The agency plans to use the RE-AIM model, which looks at an intervention’s reach, effectiveness, adoption, implementation and maintenance, as the basis for guidance on evaluating whether a REMS protects patient safety without being unnecessarily restrictive and burdensome on patient access.